Neutralisation sensitivity of the SARS-CoV-2 BA.2.87.1 variant
Sheward, D. J.; Marking, U.; Bladh, O.; Held, S.; Looyens, E.; Vandenabeele, L.; Muschiol, S.; Aguilera, K.; Norin, N. G.; Oling, S.; Westerberg, M.; Martin, D.; Hedestam, G. B. K.; Albert, J.; Thalin, C.; Murrell, B.
Show abstract
Against the backdrop of the rapid global takeover and dominance of BA.1/BA.2 and subsequently BA.2.86 lineages, the emergence of a highly divergent SARS-CoV-2 variant warrants characterization and close monitoring. Recently, another such BA.2 descendent, designated BA.2.87.1, was detected in South Africa. Here, we show using spike-pseudotyped viruses that BA.2.87.1 is less resistant to neutralisation by prevailing antibody responses in Sweden than other currently circulating variants such as JN.1. Further we show that a monovalent XBB.1.5-adapted booster enhanced neutralising antibody titers to BA.2.87.1 by almost 4-fold. While BA.2.87.1 may not outcompete other currently-circulating lineages, the repeated emergence and transmission of highly diverged variants suggests that another large antigenic shift, similar to the replacement by Omicron, may be likely in the future.
Matching journals
The top 9 journals account for 50% of the predicted probability mass.